Cardiovascular risks of COVID-19 antivirals

Antiviral treatments for COVID-19, including remdesivir, Paxlovid, molnupiravir, and antibodies like tixagevimab and cilgavimab, may carry significant cardiovascular risks, according to evidence discussed in the Acta Pharmacologica Sinica journal. The findings emphasize the need for physicians to carefully consider these potential side effects when prescribing such drugs to high-risk patients.